Table 1.
Summary of success rate of PDX models
| Tumor type | Host strain | Implantation site | Take/Engraftment rate | Passage | reference |
|---|---|---|---|---|---|
| Breast cancer | NOD/SCID&NSG NOD/SCID NSG&SCID/Beige NOD/SCID Balb/c nu/nu |
subcutaneous orthotopic orthotopic orthotopic subcutaneous |
27% 37% 21% 35% 27% |
P0 P0 P2 P0 P0 |
Jia et al.70 Derose et al.71 Zhang et al.44 Fiche et al.72 McAuliffe et al.73 |
| Non-small cell lung carcinoma | NOD/SCID NOD/SCID&NSG SCID&nude SCID&nude |
Renal capsules Subcutaneous Subcutaneous Subcutaneous |
90% 34% 39% 35% |
P0 P6 P2 P2 |
Dong et al.46 Chen et al.15 Moro et al.74 Llie et al.34 |
| Colorectal carcinoma | Balb/c nude Balb/c nude Nude NOG NSG |
Subcutaneous Subcutaneous Subcutaneous Subcutaneous Subcutaneous |
62% 59% 54% 73% 72% |
P0 P0 P0 P0 P0 |
Oh et al.16 Guan et al.75 Cybulska et al.7 Fujii et al.76 Katsiampoura et al.42 |
| Prostate cancer | NOD/SCID NSG&NOG SCID SCID |
Subrenal capsule Subrenal capsule Subrenal capsule Subcutaneous |
66% 96% 93% 58% |
P0 P0 P0 P0 |
Toivanen et al.33 Wetterauer et al.40 Wang et al.64 Wang et al.64 |
| Pancreatic cancer | Nude Nude Nude SCID |
Subcutaneous Orthotopic Subcutaneous Subcutaneous |
70% 55% 61% 66% |
P0 P0 P0 P0 |
Rubio et al.77 Rubio et al.77 Garrido et al.78 Mattie et al.79 |
| Ovarian cancer | Balb/c nude Nude SCID |
Subrenal capsule Intraperitoneal Intraperitoneal |
49% 31% 74% |
P0 P2 P0 |
Heo et al.80 Liu et al.81 Karlan et al.20 |
| Head and neck cancer | NSG NSG NSG NSG |
Subcutaneous Subcutaneous Subcutaneous Subcutaneous |
48% 79% 45% 85% |
P2 P0 P2 P0 |
Klingh et al.21 Swick et al.47 Klingh et al.82 Kimple et al.83 |